About Novartis Option Fund
The Novartis Option Fund is part of the Novartis Venture Funds. Established in 1996, the Novartis Venture Funds currently manage over US$650 million in committed capital and are invested globally in more than 50 private life sciences companies across therapeutics, vaccines, devices and diagnostics. As a financially driven corporate life science investor, the Novartis Venture Fund invests in those companies which have the potential to lead the next innovation wave in new areas that will be critical to patient care. The Novartis Venture Funds team of eight investment professionals located in Basel, Switzerland and Cambridge, Massachusetts, brings together extensive expertise in the biotech and pharmaceutical industry and venture capital.
For more information:http://www.venturefund.novartis.com Contact Information: Heptares Therapeutics Ltd Dr Malcolm Weir Phone: +44(0)20-8906-7182 Mobile: +44(0)7968-947268 E-mail: firstname.lastname@example.org Clarus Ventures Dr Michael Steinmetz Phone: +1-617-949-2200 E-mail: email@example.com MVM Life Science Partners Dr Martin Murphy Phone: +44(0)20-7557-7500 E-mail: firstname.lastname@example.org Novartis Option Fund Dr Anja Koenig Phone: +41-61-3241287 E-mail: email@example.com Citigate Dewe Rogerson (for Heptares) Dr Mark Swallow Phone: +44(0)20-7282-2948 E-mail: firstname.lastname@example.org
|SOURCE Heptares Therapeutics Ltd|
Copyright©2009 PR Newswire.
All rights reserved